• Citer

Hemodynamics and risk assessment 2 years after the initiation of upfront ambrisentan‒tadalafil in pulmonary arterial hypertension

par D'Alto, Michele;Badagliacca, Roberto;Lo Giudice, Francesco;Argiento, P.;Casu, Gavino;Corda, Marco;Correale, Michele;Ghio, S.;Greco, Alessandra;Lattanzio, Mariangela;Mercurio, Valentina;Paciocco, Giuseppe;Papa, Silvia;Prediletto, Renato;Romeo, E.;Russo, Maria Giovanna;Tayar, Alessandro;Vitulo, Patrizio;Vizza, Carmine Dario;Golino, P.;Naeije, Robert
Référence The Journal of heart and lung transplantation
Publication Publié, 2020

Article révisé par les pairs

• Détails
• Contenu

Titre:	Hemodynamics and risk assessment 2 years after the initiation of upfront ambrisentan‒tadalafil in pulmonary arterial hypertension
Auteur:	D'Alto, Michele; Badagliacca, Roberto; Lo Giudice, Francesco; Argiento, P.; Casu, Gavino; Corda, Marco; Correale, Michele; Ghio, S.; Greco, Alessandra; Lattanzio, Mariangela; Mercurio, Valentina; Paciocco, Giuseppe; Papa, Silvia; Prediletto, Renato; Romeo, E.; Russo, Maria Giovanna; Tayar, Alessandro; Vitulo, Patrizio; Vizza, Carmine Dario; Golino, P.; Naeije, Robert
Informations sur la publication:	The Journal of heart and lung transplantation
Statut de publication:	Publié, 2020
Sujet CREF:	Physiologie générale
Mots-clés:	combination therapy
	European risk score
	prognosis
	pulmonary arterial hypertension
	REVEAL risk score
	risk assessment
Note générale:	SCOPUS: ar.j
	DecretOANoAutActif
Langue:	Anglais
Identificateurs:	urn:issn:1053-2498
	info:doi/10.1016/j.healun.2020.08.016
	info:pii/S105324982031706X
	info:scp/85090698574